Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research report report published on Wednesday. The firm issued a hold rating on the medical research company’s stock.

Accelerate Diagnostics Stock Performance

AXDX opened at $1.01 on Wednesday. The business’s fifty day moving average is $1.13 and its two-hundred day moving average is $3.74. The company has a market cap of $14.72 million, a price-to-earnings ratio of -0.19 and a beta of 0.51. Accelerate Diagnostics has a one year low of $0.83 and a one year high of $11.90.

Institutional Trading of Accelerate Diagnostics

Several institutional investors and hedge funds have recently made changes to their positions in AXDX. Swiss National Bank lifted its position in shares of Accelerate Diagnostics by 19.0% in the first quarter. Swiss National Bank now owns 85,300 shares of the medical research company’s stock valued at $123,000 after acquiring an additional 13,600 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Accelerate Diagnostics by 17.9% in the first quarter. JPMorgan Chase & Co. now owns 418,359 shares of the medical research company’s stock valued at $602,000 after acquiring an additional 63,513 shares in the last quarter. HighTower Advisors LLC lifted its position in shares of Accelerate Diagnostics by 115.6% in the first quarter. HighTower Advisors LLC now owns 37,302 shares of the medical research company’s stock valued at $53,000 after acquiring an additional 20,000 shares in the last quarter. Bank of Montreal Can purchased a new stake in shares of Accelerate Diagnostics in the first quarter valued at $27,000. Finally, Baird Financial Group Inc. lifted its position in shares of Accelerate Diagnostics by 15.5% in the first quarter. Baird Financial Group Inc. now owns 1,741,547 shares of the medical research company’s stock valued at $2,508,000 after acquiring an additional 233,478 shares in the last quarter. 17.14% of the stock is currently owned by hedge funds and other institutional investors.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.